WO2012028826A1 - Nucléus enrobé d'un revêtement filmogène aux propriétés antibactériennes et cicatrisantes et procédé d'obtention - Google Patents
Nucléus enrobé d'un revêtement filmogène aux propriétés antibactériennes et cicatrisantes et procédé d'obtention Download PDFInfo
- Publication number
- WO2012028826A1 WO2012028826A1 PCT/FR2011/051994 FR2011051994W WO2012028826A1 WO 2012028826 A1 WO2012028826 A1 WO 2012028826A1 FR 2011051994 W FR2011051994 W FR 2011051994W WO 2012028826 A1 WO2012028826 A1 WO 2012028826A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleus
- eps
- pearl
- hyd
- oyster
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 30
- 238000000576 coating method Methods 0.000 title claims description 13
- 239000011248 coating agent Substances 0.000 title claims description 12
- 229920002444 Exopolysaccharide Polymers 0.000 claims abstract description 88
- 241000490567 Pinctada Species 0.000 claims abstract description 33
- 239000003899 bactericide agent Substances 0.000 claims abstract description 31
- 239000000022 bacteriostatic agent Substances 0.000 claims abstract description 31
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 11
- 230000000975 bioactive effect Effects 0.000 claims abstract description 10
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 4
- 241000237502 Ostreidae Species 0.000 claims description 52
- 235000020636 oyster Nutrition 0.000 claims description 52
- 230000008569 process Effects 0.000 claims description 25
- 238000007654 immersion Methods 0.000 claims description 17
- 241000894006 Bacteria Species 0.000 claims description 14
- 108010070741 Tachypleus tridentatus tachyplesin peptide Proteins 0.000 claims description 12
- ZJQFYZCNRTZAIM-PMXBASNASA-N tachyplesin Chemical compound C([C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@H](C(N[C@H]2CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=3C=CC=CC=3)NC(=O)[C@@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](N)CCCCN)CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C(=O)N1)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZJQFYZCNRTZAIM-PMXBASNASA-N 0.000 claims description 12
- 238000002054 transplantation Methods 0.000 claims description 12
- 239000011324 bead Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 241000195493 Cryptophyta Species 0.000 claims description 8
- 210000000981 epithelium Anatomy 0.000 claims description 8
- 108010002069 Defensins Proteins 0.000 claims description 6
- 102000000541 Defensins Human genes 0.000 claims description 6
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 5
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 239000011049 pearl Substances 0.000 description 40
- 229920002401 polyacrylamide Polymers 0.000 description 34
- 239000000243 solution Substances 0.000 description 23
- 230000001580 bacterial effect Effects 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000003385 bacteriostatic effect Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000035876 healing Effects 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 238000011109 contamination Methods 0.000 description 7
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000013535 sea water Substances 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- -1 for example Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000607598 Vibrio Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009313 farming Methods 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 241000217377 Amblema plicata Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000237536 Mytilus edulis Species 0.000 description 2
- 241001464019 Pinctada margaritifera Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000010984 cultured pearl Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 235000020638 mussel Nutrition 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000004621 scanning probe microscopy Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- XJOTXKZIRSHZQV-RXHOOSIZSA-N (3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)[C@@H](C)O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@@H]4CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@@H](NC1=O)[C@@H](C)CC)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](Cc1cnc[nH]1)NC3=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N2)C(=O)NCC(=O)N4)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XJOTXKZIRSHZQV-RXHOOSIZSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000590031 Alteromonas Species 0.000 description 1
- 241000217375 Amblema Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 241000052343 Dares Species 0.000 description 1
- 101710164770 Drosomycin Proteins 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000206596 Halomonas Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- 101710164547 Moronecidin Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000490568 Pinctada fucata Species 0.000 description 1
- 241001490476 Pinctada maxima Species 0.000 description 1
- 241000193804 Planococcus <bacterium> Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000519590 Pseudoalteromonas Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000589651 Zoogloea Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010016341 bactenecin Proteins 0.000 description 1
- RHISNKCGUDDGEG-UHFFFAOYSA-N bactenecin Chemical compound CCC(C)C1NC(=O)C(C(C)C)NC(=O)C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(CCCN=C(N)N)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(N)CCCN=C(N)N)CSSCC(C(=O)NC(CCCN=C(N)N)C(O)=O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC1=O RHISNKCGUDDGEG-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- NKNAXUIXGQHWII-UHFFFAOYSA-N brevinine Natural products COC1CC(OC2C(C)OC(CC2OC)OC3CCC4(C)C5C(OC(=O)c6ccccc6)C(O)C7(C)C(O)(CCC7(O)C5(O)CC=C4C3)C(=O)C)OC(C)C1O NKNAXUIXGQHWII-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- VNUQOJUAIRBYQO-PPAUOFQQSA-N esculentin Chemical compound O([C@H]1[C@@H](OC)C[C@@H](O[C@@H]1C)O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2CC3=CC[C@@]4(O)[C@@]5(O)CC[C@](O)([C@@]5(C)[C@H](O)[C@@H](O)C4[C@@]3(C)CC2)C(C)=O)C[C@H]1OC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](OC)[C@H]1O VNUQOJUAIRBYQO-PPAUOFQQSA-N 0.000 description 1
- VNUQOJUAIRBYQO-UHFFFAOYSA-N esculentin Natural products COC1CC(OC2CCC3(C)C4C(O)C(O)C5(C)C(O)(CCC5(O)C4(O)CC=C3C2)C(=O)C)OC(C)C1OC6CC(OC)C(OC7OC(C)C(O)C(OC)C7O)C(C)O6 VNUQOJUAIRBYQO-UHFFFAOYSA-N 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229920000912 exopolymer Polymers 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010032136 gomesin Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003558 hepcidin Proteins 0.000 description 1
- 102000018511 hepcidin Human genes 0.000 description 1
- 229940066919 hepcidin Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000009448 modified atmosphere packaging Methods 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 108010036892 spinigerin Proteins 0.000 description 1
- MXSUQOOOYVELFP-LFMHPJLRSA-N spinigerin Chemical compound NC(=N)NCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCSC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 MXSUQOOOYVELFP-LFMHPJLRSA-N 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 108010053343 temporin Proteins 0.000 description 1
- 108010003434 termicin Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 108010032153 thanatin Proteins 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/50—Culture of aquatic animals of shellfish
- A01K61/54—Culture of aquatic animals of shellfish of bivalves, e.g. oysters or mussels
- A01K61/56—Culture of aquatic animals of shellfish of bivalves, e.g. oysters or mussels for pearl production
- A01K61/57—Pearl seeds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K61/00—Culture of aquatic animals
- A01K61/50—Culture of aquatic animals of shellfish
- A01K61/54—Culture of aquatic animals of shellfish of bivalves, e.g. oysters or mussels
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0334—Genetically modified Molluscs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Definitions
- the present invention relates to the field of coating of cores in the context of pearl farming (production of pearls by pearl oysters).
- the subject of the present invention is therefore a nucleus coated with a film exhibiting cicatrizing and antibacterial properties, and making it possible to reduce the mortality resulting from the insertion of said nucleus into the recipient pearl oyster and the phenomenon of nucleus rejection.
- Pearl culture is a human activity consisting of the cultivation, in the wild, of pearl oysters Pinctada sp for the production of cultured pearls.
- the first step is the collection and rearing of pearl oysters, which will serve as either donor oyster or recipient oyster.
- the graft consists of the surgical procedure in which the graft, a portion of the donor oyster coat epithelium (approximately 4 mm 2 ) is inserted into the recipient's oyster pearl pocket, in combination with a mother of pearl ball, the nucleus. Once inserted into the recipient oyster, the epithelial border of the graft multiplies and lines the pearl pocket to give the pearl sac that encompasses the nucleus.
- the pearl bag deposits layers of mother-of-pearl around the nucleus, resulting in the production of the pearl (Montagnani et al., 2009).
- the patent application JP05219856 describes the insertion in the recipient oyster, during the step of grafting and in parallel with the nucleus or with the nucleus, a solid material containing on its surface a polymer associated with an antibiotic.
- Japanese patent applications JP02308869 and JP63215609 claim the use of a polymer-coated nucleus to improve the quality of the pearls obtained, by increasing the homogeneity of the surface of the nucleus, and to reduce the phenomena of rejection and mortality, avoiding for example the colonization of the nucleus by various parasites.
- Japanese Patent Application JP02174621 discloses the use of a natural polymer for coating the nucleus, combined with an antifungal agent, for the purpose of limiting contamination during grafting.
- US Pat. No. 6,514,614 describes the coating of the nucleus by a water-soluble polymer, associated with a substance having an antibacterial activity, said polymer being partially dissolved by seawater (the dissolution rate being greater than 25%) to allow an effective decrease friction and resistance to insertion of said nucleus.
- Japanese patent application JP03183424 describes a system for coating the nucleus with a water-soluble polymer (or any other compound allowing a delayed administration), allowing the administration at a controlled rate of an antibiotic associated with said polymer.
- the subject of the invention is a nucleus coated with a film comprising one or more exopolysaccharides (EPS).
- EPS exopolysaccharides
- the EPSs are produced by gram-positive or gram-negative bacteria, archeae or algae.
- the film further comprises one or more bioactive molecules.
- said bioactive molecules are chosen from one or more bactericidal or bacteriostatic agents, one or more cicatrizing agents and / or one or more anti-inflammatory agents.
- the EPSs are chosen from among HE 800, EPS 721, M0245, GG1, HYD 657, HYD 1644, HYD 1545, GY 785, MS 907, ST 716, HYD 721, GY 772, HYD. 750, GY 768, GY 788, BI746, GY 786, GY 685, GY 686, ST 719, HYD 1574, HYD 1579, HYD 1582, HYD 1584, ST 708, ST 722, ST 342, ST 349, HYD 1625, and HYD 1666, preferably MO 245, HE 800, GG1, HYD 721 and ST 716.
- the bactericidal or bacteriostatic agent or agents are chosen from antimicrobial peptides (PAM).
- said PAM is chosen from tachyplesin or oyster defensins Cg-Defs.
- the subject of the invention is also a process for obtaining the nucleus as described above, said process comprising a step of embedding the nucleus by the EPSs by immersion in a solution containing 0.1 to 10% by weight of EPS by relative to the volume of the solution.
- the method comprises:
- the process for obtaining a film-coated nucleus comprising one or more EPSs in combination with one or more bactericidal or bacteriostatic agents comprises a step of coating the nucleus with the EPS and the agents.
- bactericidal or bacteriostatic by immersion in a solution comprising 0.05 to 10% by weight of EPS relative to the volume of the solution and 1 to 10 CMI of said bactericidal or bacteriostatic agents.
- the invention also relates to a pearl oyster comprising a nucleus as described above.
- the invention also relates to the use of the nucleus as described above or the method as described above to reduce the failure of transplantation of a recipient oyster by a nucleus, said failure consisting of a mortality or rejection of the nucleus by the recipient pearl oyster.
- the subject of the invention is also a process for grafting a recipient pearl oyster comprising inserting into the pearling pocket of the recipient pearl oyster of a graft, corresponding to the epithelium of the mantle of the donor oyster, in combination with a nucleus as described above, or with a nucleus obtained by a method as described above.
- the invention also relates to a method of manufacturing a pearl culture pearl, comprising the grafting method as described above.
- the subject of the invention is also a method for obtaining a pearl, comprising the grafting of a nucleus according to the invention, or a nucleus obtained by a method according to the invention, in combination with a portion of the mantle epithelium of the donor oyster in the pearl pocket of the recipient oyster.
- the invention also relates to a bead obtained by the process for obtaining a bead as described above, or comprising the nucleus according to the invention or a nucleus obtained by a process according to the invention, or comprising a film comprising one or several exopolysaccharides (EPS) produced by gram positive or gram negative bacteria, archeae or algae under one or more thicknesses of nacre.
- EPS exopolysaccharides
- the present invention also relates to a method for improving the quality of the pearl and / or reducing the failure of transplantation of a recipient oyster by a nucleus, said failure corresponding to a mortality or a rejection of the nucleus by the recipient pearl oyster, and said method comprising transplanting the recipient oyster by a nucleus according to the invention or by a nucleus obtained by the method for obtaining a nucleus according to the invention.
- the present invention also relates to the use of the nucleus according to the invention or of the nucleus obtained by the process for obtaining a nucleus according to the invention for reducing the failure of transplantation of a recipient oyster by a nucleus, said failure consisting of mortality or rejection of the nucleus by the recipient pearl oyster and / or to improve the quality of the pearl obtained.
- Nucleus element, generally spherical, formed of a natural compound (for example in mother-of-Mississippi mussel, Amblema plicata) or synthetic (for example Bironite) introduced into the recipient oyster during the graft stage, and serving as a support for the nacre deposit by the recipient pearl oyster. Said nucleus may be coated with particular substances to improve the quality of the pearl obtained.
- Periodicculture human activity for the production of cultured pearl pearl oysters, generally of the genus Pinctada sp.
- Bactericidal agent substance having a bactericidal action, ie causing the death of bacteria.
- Bacteriostatic agent means a substance having a bacteriostatic action, i.e. blocking the growth, growth and / or division of bacteria.
- MIC minimum inhibitory concentration. It corresponds to the minimum concentration from which an agent inhibits the visible growth of a microorganism after incubation on the night.
- the methods for determining the MIC of an agent are well known in the state of the art.
- Healing refers to an agent capable of promoting healing, or healing of a wound, specifically an open wound, such as an incision.
- “Mother-of-pearl” a biomineralized structure composed of aragonite crystals (constituting nearly 90% of mother-of-pearl) and conchyoline.
- Aragonite is a chemical compound of formula CaC0 3 + Sr traces; Pb; Zn.
- pearl production results from the deposit of nacre on a nucleus inserted into the recipient oyster during the grafting stage.
- the nucleus transplantation stage generally has a high failure rate, due to poor healing of the recipient oyster at the incision made during grafting or bacterial contamination.
- the cores used in pearl culture are increasingly covered with a coating to reduce the failure of the graft stage.
- the present invention therefore relates to a nucleus coated or coated with a film comprising one or more exopolysaccharides (EPS).
- EPS exopolysaccharides
- the EPS film would have healing properties, to accelerate the healing of wounds induced by the grafting step, and thus reduce the mortality of the recipient oyster leading to failure of the graft. It has been shown that certain bacteria have the ability to synthesize, under controlled conditions, exopolymers including exopolysaccharides (EPS), in response to conditions of nutritional imbalance.
- Exopolysaccharides can be defined as macromolecules formed from the sequence of similar carbohydrates (commonly called sugars or dares). These exopolysaccharides can be produced on an industrial scale, and have, among other properties, adhesive properties (related to the function of these molecules in nature) and film-forming properties.
- EPS can be produced by many microorganisms such as gram-positive or gram-negative bacteria, archaea, fungi, and some algae.
- EPS are produced by gram-positive or gram-negative bacteria, archeae or algae.
- EPS can be extracted from microorganism cultures by well-known physical or chemical extraction methods such as sonication, centrifugation, alkaline treatment, ethanol extraction, enzymatic extraction, etc.
- the EPS can be chosen from those produced by marine organisms such as Bacillus, Halomonas, Planococcus, Enterobacter, Alteromonas, Pseudoalteromonas, Rhodococcus, Zoogloea, Cyanobacteria, Vibrio, as described in Satpute et al. . (Biotechnology Advances 2010, 28: 436-450). If the taxonomy were to be modified, one skilled in the art could adapt the taxonomy changes to deduce the EPS that can be used in the invention.
- EPS can be obtained by fermentation of bacteria from deep hydrothermal ecosystems. More particularly, these EPS are those synthesized under controlled conditions (nutritional imbalance generated by a high carbon / nitrogen ratio due to a carbohydrate enriched nutritional medium) during the fermentation of bacteria from deep hydrothermal ecosystems (see for example Guezennec, J. (2002) Deep Sea Hydrothermal Winds: A Novel Source of innovative Bacterial Exopolysaccharides of Biotechnological Interest Journal of Industrial Microbiology & Biotechnology 29: 204- According to one embodiment, the EPSs are chosen from the group comprising uncharged (or neutral) EPSs, such as, for example, GG1.
- the EPSs are chosen from the group comprising charged EPSs, such as, for example, HE800 and MO245.
- the EPSs may be selected from HE 800,
- the EPSs are native.
- the EPS can be chemically or physically modified (as for example by adding group (s) sulfate, acetate, lactate, succinate or pyruvate).
- the EPS film is continuous around the nucleus.
- the invention also relates to a nucleus coated with a film comprising one or more EPS and one or more bioactive molecules.
- these bioactive molecules are bactericidal or bacteriostatic agents.
- a bactericidal or bacteriostatic agent on the nucleus makes it possible to limit the occurrence of bacterial contaminations in the recipient oyster, which can lead to a rejection of the nucleus or to the death of the oyster.
- these bioactive molecules are cicatrizing or anti-inflammatory agents such as collagen, fibrinogen, laminin, or growth factors.
- the bactericidal or bacteriostatic agents are chosen from chemical antibiotics such as, for example, tetracycline, kanamycin, sulfamonomethoxyne ampicillin.
- the bactericidal or bacteriostatic agents are chosen from antimicrobial peptides (PAM).
- Antimicrobial peptides are innate immune effector molecules, conserved during evolution and widespread throughout the living kingdom.
- PAMs are generally characterized by a high representativeness in cationic and hydrophobic amino acids. These molecules are most often amphiphilic essential for their interaction with bacterial membranes (Bulet et al., 2004).
- PAMs kill microorganisms, either by permeabilizing their membrane by a detergent-like effect or by the formation of pores, by blocking the synthesis of peptidoglycan component of the bacterial wall, or by the inhibition of bacterial metabolic pathways (Brodgen et al., 2005).
- PAM Compared to the generally used chemical antibiotics, PAM has the advantage of being completely biodegradable. They appear as good candidates in substitution for conventional chemical antibiotics, because of their biological properties. Indeed, they have a broad spectrum of antimicrobial activity, little specificity, different modes of action and a safety on the environment.
- PAMs can be produced by chemical synthesis or expression in bacterial or yeast recombinant (cloning, expression, purification) systems.
- PAM may belong to the family of alpha-helical linear PAMs, to the family of PAMs with overrepresentation in one or more amino acids, to the family of hairpin PAMs (beta Hairpin) with 1 or 2 disulfide bridges, or cyclic PAM and alpha helix families with 3 or more disulfide bridges (Bulet et al., Immunological reviews, 2004, 198: 169-184; Brogden, Nature Review Microbiology 2005, 3: 238-250).
- linear alpha-helical PAM examples include, but are not limited to, cecropin, stomoxyne, ponericin, spinigerin, oxyopinin, cupienin, clavanin, styeline, pardaxine, misgurine, pleurocidin, parasin, oncorhyncin, moronecidin, magainin, temporin, cathelicidin and indolicidin.
- PAM enriched in one or more amino acids, proline, arginine, glycine, or tryptophan include, but are not limited to, bactenicins, PR-39, abaecins, apidaecins, drosocine, pyrrhocoricins, Cg-Prp, prophenine, and indolicin. .
- hairpin PAM containing 2 to 4 cysteines include, but are not limited to, tachyplesin, protectrin, thanatin, androctonine, gomesin, polyphemusin, hepcidin, brevinine, esculentin, tigerinin and bactenecin.
- cyclic PAMs containing 6 or more cysteine or open-cycle residues include, but are not limited to, defensins (vertebrates, invertebrates, or plants), proin, heliomicin, drosomycin, ASABF, pBD, penaeidines, ALF and big-defensins.
- defensins verbrates, invertebrates, or plants
- heliomicin heliomicin
- drosomycin ASABF
- pBD penaeidines
- ALF big-defensins
- invertebrate defensins are defenses of oyster Cg-Defs or defensins of MGD mussels.
- the PAM is chosen from tachyplesin and oyster defensins Cg-Defs.
- the PAMs are synthesized by chemical synthesis. According to another embodiment of the invention, the PAMs are synthesized by biological synthesis in a bacterial or fungal recombinant system and preferably in a yeast system.
- the mortality or rejection of nucleus following transplantation of the recipient oyster generally occurs during the 45 days following the operation, mainly during the first 3 weeks following the intervention.
- the PAMs are associated with said EPS film stably.
- the film comprising EPS and optionally bacteriostatic or bactericidal agents is resistant to washing with seawater and is stable for more than 3 weeks, preferably more than one month at varying temperatures. between 4 and 30 ° C.
- the film including EPS and optionally, bacteriostatic or bactericidal agents do not dissolve when placed in contact with seawater (Example 1) for at least 3 weeks.
- the film comprising EPS and optionally bacteriostatic or bactericidal agents retains a bacterial growth inhibition activity for more than 3 weeks, preferably more than 1 month, at a temperature of 37. ° C.
- the association between the EPS film and the bacteriostatic or bactericidal agent (s) such as PAMs results from an adsorption phenomenon or a chemical reaction between the EPSs and said agents.
- the present invention also relates to a process for coating the pearl culture nucleus with a film comprising one or more exopolysaccharides of bacterial origin.
- said method comprises a first step of immersing the nucleus in an aqueous solution of EPS, preferably an EPS solution in osmosis water.
- said aqueous EPS solution has an EPS concentration of 0.1 to 10% w / v, more preferably 0.5 to 5, still more preferably 1% by weight of EPS per volume of the aqueous solution.
- said first step of immersing the nucleus in a solution containing one or more EPS is carried out at a constant temperature, preferably at room temperature (ie from 15 to 25 ° C.), more preferably approximately 20 ° C.
- said first step of immersing the nucleus in a solution containing one or more EPS is preferably carried out for 1 to 60 minutes, more preferably for 5 to 20 minutes, more preferably 10 minutes.
- said first step of immersing the nucleus in a solution containing one or more EPS is carried out at a constant temperature, preferably from 1 to 10 ° C, more preferably about 4 ° C.
- said first step of immersing the material in a solution containing one or more EPS is carried out preferably for 1 to 3 hours, more preferably for about 2 hours.
- the coated nucleus is then dried under vacuum.
- the first step described above is followed by a second step comprising immersing the nucleus in a solution comprising one or more bactericidal or bacteriostatic agents at a concentration. from 1 to 10 CMI, preferably 10 CMI.
- the bactericidal or bacteriostatic agent is in solution in a biologically acceptable polar solvent such as water (for example osmosis water), ethanol, trifluoroethanol (CF 3 CH 2 OH, TFE) or their mixture, for example water / TFE, preferably trifluoroethanol (CF 3 CH 2 OH) or osmosis water.
- a biologically acceptable polar solvent such as water (for example osmosis water), ethanol, trifluoroethanol (CF 3 CH 2 OH, TFE) or their mixture, for example water / TFE, preferably trifluoroethanol (CF 3 CH 2 OH) or osmosis water.
- the second nucleus immersion step is carried out at a constant temperature, preferably from 1 to 10 ° C, more preferably about 4 ° C.
- said second nucleus immersion step is preferably carried out for 24 to 120 hours, more preferably for 48 to 96 hours, even more preferably 72 hours.
- said second nucleus immersion step is carried out for 12 to 48 hours, preferably 12 to 24 hours, and more preferably for 24 hours.
- the second nucleus immersion step is carried out at a constant temperature, preferably at ambient temperature (from 20 to 30 ° C.), more preferably to about 25 ° C.
- said second nucleus immersion step is preferably carried out for 30 minutes to 3 hours, preferably for 1 to 2 hours, even more preferably for about 1:30.
- the coated nucleus is then dried under vacuum.
- said method optionally comprises a step of rinsing the nucleus between the first immersion step and the second immersion stage.
- the nucleus is rinsed with a volume of 10 to 1000 ml of distilled water, preferably 100 to 300 ml of distilled water, more preferably about 200 ml of distilled water.
- the invention also relates to a process for obtaining a nucleus coated with a film comprising one or more EPS and one or more bacteriostatic or bactericidal agents, said process comprising a single step of immersing the nucleus in a solution comprising EPS and bacteriostatic or bactericidal agents.
- the EPS are present in the solution at a concentration of 0.05 to 10% by weight relative to the total volume of the solution, preferably from 0.1 to 5%, more preferably at a concentration of 1%.
- the bactericidal or bacteriostatic agents are present in the solution at a concentration of 1 to 10 CMI.
- this immersion step is carried out at a constant temperature of 1 to 10 ° C, preferably 4 ° C, and for 12 to 128 hours, preferably for 48 to 96 hours, and more preferably for 72 hours.
- the coated nucleus according to the invention, or obtained according to a process according to the invention is stored at 4 ° C.
- the coated core according to the invention, or obtained according to a process according to the invention is stored at ambient temperature.
- the nucleus is of natural origin, more preferably said nucleus is in Mississippi mother-of-pearl belonging to the genus Amblema sp., Preferably Amblema plicata.
- nucleus are those sold by Aming (Standard Aming) or by Poe Import.
- said nucleus has a diameter of 1 to
- said nucleus has a diameter of 2 to
- the invention also relates to an oyster comprising a nucleus as described above or obtained by a method as described above.
- the oyster belongs to the genus Pinctada sp., More preferably to the species Pinctada fucata, Pinctada maxima, Pinctada margaritifera.
- the subject of the invention is also a process for grafting a recipient pearl oyster comprising inserting into the pearling pocket of the recipient pearl oyster of a graft, corresponding to the epithelium of the mantle of the donor oyster, in combination with a nucleus as described above, or obtained by a method as described above.
- the grafting method comprises (i) manually opening the recipient pearl oyster, (ii) making an incision in the tissues of the recipient pearl oyster to access the pearling bag and allow, in a third step (iii) the insertion into the pearling pocket of the recipient pearl oyster of a graft, corresponding to a portion of the donor oyster coat epithelium (about 4 mm) 2 ), in combination with a core coated with an EPS film as described above.
- the invention also relates to a method of manufacturing a pearl culture pearl, comprising the grafting method as described above.
- the present invention also relates to a process for obtaining a bead comprising the use of the coated nucleus as described above, or obtained according to a coating process as described above.
- the process for obtaining a pearl comprises the grafting of a nucleus according to the invention in the pearling pocket of a recipient oyster, in combination with a part of the epithelium of the a donor oyster.
- said process for producing or obtaining a pearl comprises a first step comprising the collection and rearing pearl oysters, preferably belonging to the genera and species mentioned above, to obtain donor pearl oysters and recipient pearl oysters.
- the donor and recipient pearl oysters are then cleaned to remove any parasites.
- said production method further comprises, following the grafting, a step of culturing the recipient pearl oysters, preferably for a period of 10 to 24 months, preferably from 12 to 20 months, even more preferably from 16 to 18 months.
- the epithelial border of the graft multiplies and lines the pearl pocket, to give a perlier bag encompassing the nucleus, and will deposit layers of mother of pearl around the nucleus, resulting in the production of a pearl.
- the invention also relates to a bead obtained by the process for obtaining a bead as described above.
- the invention also relates to a bead comprising a core coated according to the invention, or a nucleus obtained by a process according to the invention.
- the present invention also relates to a pearl whose core is covered with a film of EPS, preferably EPS produced by gram-positive or gram-negative bacteria, archeae or algae, optionally in combination with one or more bioactive molecules. .
- EPS preferably EPS produced by gram-positive or gram-negative bacteria, archeae or algae
- the present invention also relates to a bead comprising a film of EPS, preferably EPS produced by gram-positive or gram-negative bacteria, archeae or algae, optionally in association with one or more bioactive molecules under one or more thicknesses of nacre.
- EPS preferably EPS produced by gram-positive or gram-negative bacteria, archeae or algae
- the bead has a size, preferably a diameter of 2 to 20 mm, preferably 5 to 15 mm, even more preferably 6.8 to 10 mm.
- the presence of a film around the nucleus as described in the invention has several advantages: Improvement of the homogeneity of the surface of the nucleus, and / or
- the present invention also relates to a method for improving the homogeneity of a nucleus, comprising coating said nucleus with a film as described in the present invention.
- the present invention also relates to a method for improving the quality of the pearl obtained during the grafting of a recipient oyster, comprising the use of a nucleus according to the invention.
- the use of the nucleus according to the invention during the grafting step limits the appearance of surface defects on the bead.
- the present invention also relates to a method of reducing the failure of transplantation of a recipient oyster by a nucleus, said failure corresponding to a mortality or rejection of the nucleus by the recipient pearl oyster, and said method comprising the transplant of the recipient oyster with a nucleus according to the invention or obtained by the process for obtaining a nucleus according to the invention.
- the present invention also relates to a method of inhibiting the rejection of the nucleus during the graft, said method comprising the use of a coated nucleus according to the invention during the grafting.
- the present invention further relates to a method of reducing the mortality of recipient oysters following the grafting step, comprising using a coated nucleus according to the invention during grafting.
- the mortality prevented by the method of the invention is due to an infection of the incision made during the graft.
- the present invention also relates to the use of the nucleus according to the invention or obtained by the process for obtaining a nucleus according to the invention for reducing the failure of transplantation of a recipient oyster with a nucleus, said failure consisting in mortality or rejection of the nucleus by the recipient pearl oyster and / or to improve the quality of the pearl obtained.
- the present invention furthermore relates to a method of accelerating the healing of the incision performed during the graft, comprising the use of a coated nucleus according to the invention.
- the present invention also relates to a method for inhibiting microbial contamination phenomena occurring during grafting, said method comprising the use of a coated nucleus according to the invention during grafting.
- PAM as bacteriostatic or bactericidal agent allows a better respect of the environment compared to the use of conventional chemical antibiotics, and health, the muscle of pearl oyster can be consumed raw.
- Figure 1 is an assembly of photos obtained by scanning microscopy, uncoated nuclei (a) and coated (b, c and d). The marks correspond to voluntary tearing to reinforce the presence of the film.
- Figure 2 is an assembly of Petri dishes after culturing with bacterial solutions incubated with nuclei.
- nuclei (a) nucleus uncoated or coated with EPS alone, (b) nucleus coated with a combination EPS / PAM without rinsing, (c) core coated with an EPS / PAM combination and rinsed with seawater or water MilliQ.
- Example 1 presence of EPS film Nuclei were coated with a film comprising EPS M0245 and optionally tachyplesin. These nuclei were obtained by a two-step process:
- Figure 1 obtained by scanning microscopy unambiguously shows the presence of a film.
- Figures b and c show the presence of the film after a tear and Figure d shows that the film remains stable after washing with water and / or TFE.
- Standard diameter nuclei were used for studies on the influence of surface pretreatment by biopolymers derived from bacterial fermentation.
- the nuclei are coated with a film comprising EPS M0245 alone or in combination with tachyplesin.
- nuclei are obtained by a one-step process: immersion of the nuclei in a solution comprising 0.1% of M0245 and optionally 70 mg / l (ie 10 CMI) of tachyplesin for 48 h at 4 ° C.
- nuclei were rinsed with 200 ml of seawater or MilliQ water before being dried. All the nuclei were then dried under vacuum.
- a classical bacterial growth inhibition test was carried out on these nuclei: the nuclei were brought into contact with a bacterial solution in the exponential phase of growth of the strain Vibrio (Vibrio Pmar02-149) isolated from Pinctada margaritifera during a transplant in Tahiti for 18h at 30 ° C. The bacterial growth is then measured spectrophotometrically at an optical density of 630 nm. The bacterial solution is then spread on petri dish (Zobell Agar medium) and the colonies developed are then counted. Figure 2a shows that the presence of uncoated nuclei does not inhibit bacterial growth. Similar results were obtained with nuclei coated only with a film comprising EPS.
- Figure 2b shows that the presence of film-coated nuclei comprising an EPS + PAM combination inhibits bacterial growth.
- FIG. 2c shows that the antibacterial activity of the nuclei coated with a film comprising an EPS + PAM combination is preserved after washing the nuclei.
- the antimicrobial activity of the nuclei is measured by the percentage inhibition of bacterial growth after 18 hours of contact relative to the control (bacterial culture without nuclei). The percentages of inhibition measured are shown in the table below.
- EPS-coated nuclei in combination with PAM strongly inhibited bacterial growth (97 and 95% for M0245 and GG1 EPS respectively).
- Uncoated nuclei or coated with EPS M0245 and a PAM
- a film according to the invention comprising an EPS and a PAM, makes it possible to reduce the rejection of the nucleus by more than 20%.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Farming Of Fish And Shellfish (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180051837.3A CN103260395B (zh) | 2010-08-31 | 2011-08-31 | 用具有抗菌和愈合性质的成膜包衣包被的核及其获得方法 |
JP2013526535A JP6158083B2 (ja) | 2010-08-31 | 2011-08-31 | 抗菌及び瘢痕特性を有する膜形成被膜を用いた核被膜及びその取得方法 |
AU2011298216A AU2011298216B2 (en) | 2010-08-31 | 2011-08-31 | Nucleus coated with a film-forming coating having antibacterial and cicatrizing properties, and method for obtaining same |
US13/819,367 US20130152865A1 (en) | 2010-08-31 | 2011-08-31 | Nucleus coated with a film-forming coating having antibacterial and cicatrizing properties, and method for obtaining same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1056889A FR2964014B1 (fr) | 2010-08-31 | 2010-08-31 | Nucleus enrobe d'un revetement filmogene aux proprietes antibacteriennes et cicatrisantes et procede d'obtention. |
FR1056889 | 2010-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012028826A1 true WO2012028826A1 (fr) | 2012-03-08 |
Family
ID=43828328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2011/051994 WO2012028826A1 (fr) | 2010-08-31 | 2011-08-31 | Nucléus enrobé d'un revêtement filmogène aux propriétés antibactériennes et cicatrisantes et procédé d'obtention |
Country Status (6)
Country | Link |
---|---|
US (1) | US20130152865A1 (fr) |
JP (1) | JP6158083B2 (fr) |
CN (1) | CN103260395B (fr) |
AU (1) | AU2011298216B2 (fr) |
FR (1) | FR2964014B1 (fr) |
WO (1) | WO2012028826A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016516684A (ja) * | 2013-03-14 | 2016-06-09 | ブルエコ ベネルクス ベスローテン フェンノートシャップ | 殺生物組成物、及び水又は水と接触する表面の処理方法。 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108564222B (zh) * | 2018-04-23 | 2022-03-01 | 浙江中医药大学 | 优化算法及优化药用珠核生产工艺的方法 |
CN114933644B (zh) * | 2022-06-15 | 2023-08-22 | 河南师范大学 | 一种泥鳅抗菌肽Ma-sHep及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63215609A (ja) | 1987-03-02 | 1988-09-08 | Akira Sunami | 真珠母貝表面の防汚および防虫被覆剤 |
JPH02174621A (ja) | 1988-12-27 | 1990-07-06 | Mikimoto:Kk | 真珠核 |
JPH02203724A (ja) * | 1989-02-01 | 1990-08-13 | Obata Terumi | 真珠養殖用の核及びその製造方法 |
JPH02308869A (ja) | 1989-05-24 | 1990-12-21 | Sunamiya:Kk | 真珠貝母貝用塗料 |
JPH0387128A (ja) * | 1989-12-11 | 1991-04-11 | Obata Terumi | 真珠養殖用の核及びその製造方法 |
JPH03183424A (ja) | 1989-12-11 | 1991-08-09 | Pearl Res Center:Kk | 抗生物質徐放真珠養殖用核の製造方法 |
JPH05219856A (ja) | 1991-10-03 | 1993-08-31 | Eisai Co Ltd | 薬物含有固形物を挿入する真珠養殖方法 |
US6514614B1 (en) | 2000-05-12 | 2003-02-04 | Koken Co. Ltd | Coated nucleus for a cultured pearl |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3361830B2 (ja) * | 1992-03-30 | 2003-01-07 | 生化学工業株式会社 | 抗菌性組成物及びそれを有効成分とする薬剤 |
JP3151068B2 (ja) * | 1992-09-29 | 2001-04-03 | 日本配合飼料株式会社 | 真珠貝への真珠核挿入方法 |
FR2760022B1 (fr) * | 1997-02-25 | 1999-04-30 | Ifremer | Souche bacterienne marine du genre vibrio, polysaccharides hydrosolubles produits par cette souche, et leurs utilisations |
DE60236374D1 (de) * | 2001-03-23 | 2010-06-24 | Advanced Bionutrition Corp | Verfahren zur Herstellung eines Futtermittels enthaltend Bakterien für Aquakultur und seiner Verwendung |
US20030027258A1 (en) * | 2001-08-02 | 2003-02-06 | Chang Fang-Tseh Frank | Methods and compositions for pearl oyster cultivation |
EP1581619B1 (fr) * | 2002-09-12 | 2011-04-13 | Metabolix, Inc. | Production de polyhydroxyalkanoate par des voies d'aldehyde deshydrogenase coenzyme a-dependante |
US20040235738A1 (en) * | 2003-05-16 | 2004-11-25 | Academia Sinica | Novel antimicrobial peptide isolated from penaeus monodon |
FR2871379B1 (fr) * | 2004-06-14 | 2006-09-29 | Ifremer | Utilisation de derives polysaccharidiques hautement sulfates et de faible masse molaire pour moduler l'angiogenese |
WO2008027235A1 (fr) * | 2006-08-25 | 2008-03-06 | University Of New Mexico | Procédés et compositions destinés au contrôle de maladies en aquaculture |
-
2010
- 2010-08-31 FR FR1056889A patent/FR2964014B1/fr active Active
-
2011
- 2011-08-31 US US13/819,367 patent/US20130152865A1/en not_active Abandoned
- 2011-08-31 AU AU2011298216A patent/AU2011298216B2/en active Active
- 2011-08-31 WO PCT/FR2011/051994 patent/WO2012028826A1/fr active Application Filing
- 2011-08-31 JP JP2013526535A patent/JP6158083B2/ja active Active
- 2011-08-31 CN CN201180051837.3A patent/CN103260395B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63215609A (ja) | 1987-03-02 | 1988-09-08 | Akira Sunami | 真珠母貝表面の防汚および防虫被覆剤 |
JPH02174621A (ja) | 1988-12-27 | 1990-07-06 | Mikimoto:Kk | 真珠核 |
JPH02203724A (ja) * | 1989-02-01 | 1990-08-13 | Obata Terumi | 真珠養殖用の核及びその製造方法 |
JPH02308869A (ja) | 1989-05-24 | 1990-12-21 | Sunamiya:Kk | 真珠貝母貝用塗料 |
JPH0387128A (ja) * | 1989-12-11 | 1991-04-11 | Obata Terumi | 真珠養殖用の核及びその製造方法 |
JPH03183424A (ja) | 1989-12-11 | 1991-08-09 | Pearl Res Center:Kk | 抗生物質徐放真珠養殖用核の製造方法 |
JPH05219856A (ja) | 1991-10-03 | 1993-08-31 | Eisai Co Ltd | 薬物含有固形物を挿入する真珠養殖方法 |
US6514614B1 (en) | 2000-05-12 | 2003-02-04 | Koken Co. Ltd | Coated nucleus for a cultured pearl |
Non-Patent Citations (4)
Title |
---|
BROGDEN, NATURE REVIEW MICROBIOLOGY, vol. 3, 2005, pages 238 - 250 |
BULET ET AL., IMMUNOLOGICAL REVIEWS, vol. 198, 2004, pages 169 - 184 |
GUEZENNEC, J.: "Deep- sea hydrothermal vents: A new source of innovative bacterial exopolysaccharides of biotechnological interest?", JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY, vol. 29, 2002, pages 204 - 208, XP008039157, DOI: doi:10.1038/sj.jim.7000298 |
SATPUTE ET AL., BIOTECHNOLOGY ADVANCES, vol. 28, 2010, pages 436 - 450 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016516684A (ja) * | 2013-03-14 | 2016-06-09 | ブルエコ ベネルクス ベスローテン フェンノートシャップ | 殺生物組成物、及び水又は水と接触する表面の処理方法。 |
Also Published As
Publication number | Publication date |
---|---|
JP6158083B2 (ja) | 2017-07-05 |
US20130152865A1 (en) | 2013-06-20 |
AU2011298216A1 (en) | 2013-03-14 |
CN103260395A (zh) | 2013-08-21 |
FR2964014B1 (fr) | 2013-04-05 |
JP2013536681A (ja) | 2013-09-26 |
CN103260395B (zh) | 2016-11-16 |
FR2964014A1 (fr) | 2012-03-02 |
AU2011298216B2 (en) | 2016-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Martinez et al. | Fungal biofilms: relevance in the setting of human disease | |
Klochkova et al. | Host–parasite interactions and host species susceptibility of the marine oomycete parasite, Olpidiopsis sp., from Korea that infects red algae | |
CH675535A5 (fr) | ||
WO2012028826A1 (fr) | Nucléus enrobé d'un revêtement filmogène aux propriétés antibactériennes et cicatrisantes et procédé d'obtention | |
EP3558294B1 (fr) | Composition à base de composés thiosulfinate et/ou de thiosulfonate pour son utilisation dans la prévention des infections bactériennes chez les animaux aquatiques | |
EP2588544A1 (fr) | Exopolysaccharides pour la prévention et la lutte contre la formation de biofilms | |
US5451515A (en) | Production and recovery of tyrosinase from melanin-synthesizing bacteria | |
Nuc et al. | From chitin to chitosan–a potential natural antimicrobial agent | |
EP3525593B1 (fr) | Procédé d'élicitation d'une plante au moyen d'extraits de champignons macroscopiques comestibles | |
WO2012080660A1 (fr) | Nucléus recouvert de pha | |
JP2013536681A5 (fr) | ||
EP3017069B1 (fr) | Utilisation d'une bactérie isolée du genre pseudoalteromonas, cyclolipopeptides et leurs utilisations | |
Sun et al. | The immunomodulation of inducible hydrogen sulfide in Pacific oyster Crassostrea gigas | |
EP3411442B1 (fr) | Procédé de prévention du dépôt de biosalissures sur un matériau en contact avec un milieu aqueux | |
US4740466A (en) | Induction of settlement and metamorphosis in Crassostrea virginica by melanin-synthesizing bacteria | |
Liu et al. | Biofilm formation under high temperature causes the commensal bacteria Bacillus cereus WPySW2 to shift from friend to foe in Neoporphyra haitanensis in vitro model | |
EP1456352B1 (fr) | Milieu de culture solide pour micro-organismes et cellules eucaryotes ainsi que son procede d'obtention | |
JP2011010637A (ja) | 二枚貝飼育剤及び二枚貝飼育法 | |
WO2024184172A1 (fr) | Procédé de préparation d'une composition issue d'holothuries vivantes | |
Perdomo | Understanding the Origins of Bioadhesion in Marine Organisms | |
CA1340859C (fr) | Induction de la fixation et de la metamorphose chez crassostrea virginica a l'aide de bacteries synthetisant de la myeline et d'ammoniac et metabolites de ladite bacterie | |
Martin et al. | Morphology and function of the skin epithelium covering the giant keyhole limpet Megathura crenulata | |
Vo et al. | Bdellovibrio bacteriovorus Predation in Dual-Species Biofilms of E. coli Prey and M. luteus Decoys | |
FR3109584A1 (fr) | Microcompartiment pour la culture de cellules de cnidaires | |
WO1998021959A1 (fr) | Utilisation de l'ascididemine et derives dans des compositions antisalissures biologiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11764819 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013526535 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13819367 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2011298216 Country of ref document: AU Date of ref document: 20110831 Kind code of ref document: A |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11764819 Country of ref document: EP Kind code of ref document: A1 |